Thèse Pour obtenir le grade de

Rapporteur Bergoin

Description

Niveau: Supérieur, Doctorat, Bac+8
Thèse Pour obtenir le grade de DOCTEUR DE L'UNIVERSITE PhD Présentée et soutenue Par Berhe Gebreegziabher Le 10 Novembre 2006 Development of Dual Vaccines for the Control of Peste des Petits Ruminants and Capripox Infections of Small Ruminants. Jury : PROF D.P. PICAVET Directeur de Thèse DR S. BERTAGNOLI Rapporteur DR R. DRILLIEN Rapporteur DR M. BERGOIN Rapporteur DR E. ALBINA Examinateur DR A. DIALLO Examinateur 1

• picavet directeur de thèse


• geographical distribution


• hppr recombinant viruses


• side when ever


• albina examinateur


• structural proteins


• aetiological agent


• drillien rapporteur


• study into practical


• patience during

Sujets

• Claire
• Muguet de mai
• Albina
• Diallo

Informations

• Publié par: profil-zyak-2012
• Publié le: 01 novembre 2006
• Nombre de lectures: 46
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Thèse
Pour obtenir le grade de

DOCTEUR DE L’UNIVERSITE

PhD

Présentée et soutenue
Par
Berhe Gebreegziabher

Le 10 Novembre 2006


Development of Dual Vaccines for the Control
of Peste des Petits Ruminants
and Capripox Infections of Small Ruminants.


Jury :
Directeur de Thèse PROF D.P. PICAVET
Rapporteur DR S. BERTAGNOLI DR R. DRILLIEN
Rapporteur DR M. BERGOIN
Examinateur DR E. ALBINA
Examinateur DR A. DIALLO

1ACKNOWLEDGEMENTS




The French Ministry of Foreign Affaire in general and the CIRAD-EMVT in particular
deserve my special attention and heartily appreciation for providing me the post graduate
scholarship grant with all the privileges I enjoyed during my stay in France without
whom the realization of the present study into practical would have been a dream.

I am particularly indebted to Dr. Adama DIALLO, my advisor, for his unreserved and
enthusiastic moral support, diligence, meticulous and incalculable time devotion in
guiding me throughout the years.

I would like to express my deep sense of indebtness to Dr. Emmanuel ALBINA, my co-
advisor, for his excellent leading quality of the programme, rectifying my manuscripts,
giving constructive criticism, and constant encouragement throughout my study.

My deep thanks go to Dr. Geneviève LIBEAU, very kind colleague, available at any time
to help me. I appreciate her routine follow up of my administrative papers as well as her
constant encouragement.

I am also highly thankful to Professor P.D. PICAVET for very kindly accepting to be
Director of the Thesis. I’m very grateful as well to Dr. S. BERTAGNOLI, Dr. R.
DRILLIEN and Dr. M. BERGOIN for their dedication and commetment to accept to be
Rapporters in the Jury.

It is a very good opportunity for me to forward my special thanks and respect to Mlle.
Cécile MINET, for her unreserved help provided and for her keen interest to be to my
side when ever I am in need of her rich and experienced technical know-how.
I want to express my heartfelt thanks and appreciation to the whole staff of the Animal
health department of CIRAD-EMVT (Santé Animale) for their unforgettable hospitality
and supports they gave me and my special thanks goes to M. Olivier KWIATEK, M.
Christian LEGOFF, Mlle. Denise BASTRON and Mlle. Colette GRILLET for their
unreserved help and moral support provided to me.

My special tanks to the team of CROUS of Montpellier, to mention some, Marie Claire
PIGIERE, Florence, Nicole, Barbara etc. who have been very helpful and kind enough to
listen my concerns during my stay in France.

Last but not least, my wonderful appreciation goes to my beloved wife, W/ro Elsa
Girmay and my kids Abenezer and Delina for their moral support, encouragement and
patience during my long time absence realizing this work far away from them.








3TABLE OF CONTENTS
Title PAGE

ACKNOWLEDGEMENTS................................................................................................ 2
TABLE OF CONTENTS 4
Résumé............................................................................................................................ 6
Summary......................................................................................................................... 8
GENERAL INTRODUCTION..................................................................................... 10
List of Figures…………………………………………………………… ………….11
List of Tables ................................................................................................................ 13
List of Abbreviation …………………………………………………………………..14
CHAPTER ONE Literature review ................................................................................. 16
PESTE DES PETITS RUMINANTS ....................................................................... 17
Definition & Background 17
Symptoms ............................................................................................................. 18
Aetiologic agent and its structure. ........................................................................ 21
Viral structural proteins. ................................................................................... 22
- The Nucleocapsid (N) protein .................................................................... 22
- The Phosphoprotein (P) Protein. ................................................................ 23
- The Matrix (M) protein............................................................................... 24
- The Fusion (F) protein................................................................................ 25
- The Haemagglutinin (H) protein 26
- The Large (L) protein ................................................................................. 28
Virus non-structural proteins ............................................................................ 29
- The C protein.............................................................................................. 29
- The V protein 30
Genome............................................................................................................. 33
Transcription..................................................................................................... 35
Replication ........................................................................................................ 36
Geographic distribution ........................................................................................ 39
Economic incidence 40
Sanitary and Medical Prophylaxis ........................................................................ 41
Sanitary prophylaxis ......................................................................................... 41
Medical prophylaxis.......................................................................................... 41
SHEEP AND GOAT POX 42
Definition .............................................................................................................. 42
Symptoms ............................................................................................................. 43
Aetiological agent ................................................................................................. 44
Geographical distribution...................................................................................... 46
Sanitary and Medical Prophylaxis ........................................................................ 46
Sanitary measures ............................................................................................. 46
Medical me.............................................................................................. 47
Poxviruses as expression vectors.......................................................................... 47
Generalities ....................................................................................................... 47
Capripox virus as a vector..................................................................................... 49 Conclusion ............................................................................................................ 49
CHAPTER TWO Construction of recombinant vaccines ............................................... 51
Introduction................................................................................................................... 52
FPPRV/Capripox recombinant construction................................................................. 53
Article 1 .................................................................................................................... 54
HPPRV/Capripox recombinant construction................................................................ 61
Article 2 62
Manuscript 3 ............................................................................................................. 66
Conclusion: 94
CHAPTER THREE Comparison of promoter efficacy................................................... 95
Introduction 96
Materials and Methods.................................................................................................. 97
Recombinant vaccines .............................................................................................. 97
In vitro evaluation of H expression by the different recombinant capripox/HPPR
viruses ....................................................................................................................... 98
Evaluation of the different capripox/HPPR recombinant viruses for protection of
Goats against PPR..................................................................................................... 98
Result and discussion......................................